Amphiphilic poly(esteracetal)s as dual pH- and enzyme-responsive micellar immunodrug delivery systems

被引:27
作者
Bixenmann, Leon [1 ]
Stickdorn, Judith [1 ]
Nuhn, Lutz [1 ]
机构
[1] Max Planck Inst Polymer Res, Ackermannweg 10, D-55128 Mainz, Germany
关键词
POLYMERIC MICELLES; DRUG-DELIVERY; TRIAL; NANOMEDICINE; FORMULATION; PACLITAXEL; DESIGN;
D O I
10.1039/c9py01716j
中图分类号
O63 [高分子化学(高聚物)];
学科分类号
070305 ; 080501 ; 081704 ;
摘要
Poly(esteracetal)s are equipped with both acid-labile acetal and base-labile ester functionalities in their backbone, thus, providing dual pH-responsive degradation profiles. In this study, the cyclic esteracetal monomer 2-methyl-1,3-dioxan-4-one (MDO) was polymerised via a cationic ring-opening mechanism onto methoxy poly(ethylene glycol) (mPEG) affording amphiphilic mPEG-b-P(MDO) poly(esteracetal) block copolymers that self-assemble into well-defined monomodal micelles by direct hydration with aqueous buffers. Their pH-responsive behaviour towards rapid particle degradation was confirmed by DLS and H-1-NMR. Upon acidification or basification and lipase-mediated enzymatic hydrolysis, immediate polymer degradation and cargo release could be observed. As an example for further suitable applications, an amphiphilic immune stimulatory TLR-7 agonist (Adifectin) was co-formulated into mPEG-b-P(MDO) block copolymer micelles and its activity was investigated by TLR stimulation of RAW Blue macrophages. The degradable amphiphilic block copolymer was able to solubilize the drug more efficiently and retained its receptor activity. Consequently, mPEG-b-P(MDO) based amphiphilic poly(esteracetal)s can be considered as promising delivery systems for further immunodrugs and, thus, may contribute towards improving their translatability.
引用
收藏
页码:2441 / 2456
页数:16
相关论文
共 53 条
  • [41] Delivery technologies for cancer immunotherapy
    Riley, Rachel S.
    June, Carl H.
    Langer, Robert
    Mitchell, Michael J.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (03) : 175 - 196
  • [42] A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily
    Savage, P
    Horton, V
    Moore, J
    Owens, M
    Witt, P
    Gore, ME
    [J]. BRITISH JOURNAL OF CANCER, 1996, 74 (09) : 1482 - 1486
  • [43] Material design for lymph node drug delivery
    Schudel, Alex
    Francis, David M.
    Thomas, Susan N.
    [J]. NATURE REVIEWS MATERIALS, 2019, 4 (06) : 415 - 428
  • [44] Controlled drug delivery vehicles for cancer treatment and their performance
    Senapati, Sudipta
    Mahanta, Arun Kumar
    Kumar, Sunil
    Maiti, Pralay
    [J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2018, 3
  • [45] Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
    Singh, Akhand Pratap
    Biswas, Arpan
    Shukla, Aparna
    Maiti, Pralay
    [J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2019, 4 (1)
  • [46] Core-crosslinked polymeric micelles: Principles, preparation, biomedical applications and clinical translation
    Talelli, Marina
    Barz, Matthias
    Rijcken, Cristianne J. F.
    Kiessling, Fabian
    Hennink, Wim E.
    Lammers, Twan
    [J]. NANO TODAY, 2015, 10 (01) : 93 - 117
  • [47] Contributions of Molecular Properties to Drug Promiscuity Miniperspective
    Tarcsay, Akos
    Keseru, Gyoergy M.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (05) : 1789 - 1795
  • [48] Lymph-Node-Targeted Immune Activation by Engineered Block Copolymer Amphiphiles-TLR7/8 Agonist Conjugates
    Van Herck, Simon
    Deswarte, Kim
    Nuhn, Lutz
    Zhong, Zifu
    Catani, Joao Paulo Portela
    Li, Yupeng
    Sanders, Niek N.
    Lienenklaus, Stefan
    De Koker, Stefaan
    Lambrecht, Bart N.
    David, Sunil A.
    De Geest, Bruno G.
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2018, 140 (43) : 14300 - 14307
  • [49] Nanoparticle Delivery of Cancer Drugs
    Wang, Andrew Z.
    Langer, Robert
    Farokhzad, Omid C.
    [J]. ANNUAL REVIEW OF MEDICINE, VOL 63, 2012, 63 : 185 - 198
  • [50] Wu H., 2019, BIORXIVORG, DOI [10.1101/689604, DOI 10.1101/689604]